May 8, 2024 7:34am

Fueled by earnings’ LPS (loss-per-share) Q1 losses, missed revenue and EPS estimates while dropping share pricing

Earnings Today: Editas Medicine (EDIT), Verve Therapeutics (VERV), Vericel (VCEL), Lenz Therapeutics (LENZ) and <Caribou Therapeutics (CRBU)-last night>

I am right more often than not and investors have always been able to count on … RMi for return on investment (ROI); start thinking return on speculation

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi

 

Wednesday: The pre-open Dow futures are DOWN -0.04% or (-12 points), the S&P futures are DOWN -0.12% or (-6 pints) as the Nasdaq futures are DOWN -0.15% or (-29 points)

Stock futures were flat Wednesday,

European markets were slightly higher,

Asia-Pacific markets were weak and fell

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed UP +31.99 points or +0.08%, the S&P closed UP +6.96 points or +0.13% while the Nasdaq closed DOWN -16.69 points or -0.10%

Economic Data Docket: wholesale inventories

 

Tuesday night’s RegMed Investors (RMi) Closing Bell: “starting with sector slippage to a neutral mid-day ending with a negative close. As I had stated, “let’s not forget about volatility” … https://www.regmedinvestors.com/articles/13450

 

Q2/24:  May – 4 positive and 1 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications is focused on earnings’ LPS (loss-per-year) “numbers” the aftermarket fluctuated as the pre-open waits for an all-clear alarm, …  it is still a mix of ups, downs and mostly unknowns.

 

The BOTTOM LINE: Drip, drip, drip from last to this and some of last week’s sessions = 6 to 9 to 12 to 15 to 18 equities dropping, watch for the drips going forward …

Earnings leave share pricing ringing the toilet; as indexes closed narrowly mixed on Tuesday.

 

Watch, wait and stand-down!

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.